Biomarkers /
CDK12
Overview
Cyclin-dependent kinase 12 (CDK12) is a gene that encodes a protein that functions in the phosphorylation of the C-terminal of the large subunit of RNA polymerase II, the maintenance of genomic stability, and the process of DNA repair. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
CDK12 is altered in 3.43% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDK12 are CDK12 Mutation (1.81%), CDK12 Amplification (2.00%), CDK12 Nonsense (0.25%), CDK12 Fusion (0.13%), and CDK12 Loss (0.03%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of CDK12 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.